2004-10-28 - Female - 29 Years old
175550
| Adverse reaction report number | 175550 |
| Latest AER version number | 0 |
| Market authorization holder AER number | CA200402356 |
| Initial received date | 2004-10-28 |
| Latest received date | 2005-11-16 |
| Age | 29 Years |
| Gender | Female |
| Weight | N/A |
| Type of report | Study |
| Reporter type | Pharmacist |
| Source of report | MAH |
| Report outcome | Unknown |
| Serious report? | Yes |
Reason for seriousness
| Death | |
| Disability | |
| Cogenital anomaly | Yes |
| Life threateting | |
| Hospitalization | |
| Other medically important |
| Product description | Dosage form | Health product role | Route of administration | Dose | Frequency | Therapy duration | Indication(s) |
|---|---|---|---|---|---|---|---|
| COMBIVIR | TABLET | Suspect | Oral | 1 Dosage forms | 2 every 1 Day(s) | ||
| REYATAZ | CAPSULE | Suspect | Oral | 400 Milligram | every 1 Day(s) | 148 Day(s) | |
| IRON SUPPLEMENT | NOT SPECIFIED | Concomitant | Unknown |
| MedDRA version: v.21.1 | |
| Adverse reaction terms | Reaction duration |
|---|---|
| Abortion | |
| Congenital anomaly | |
| Cytogenetic abnormality | |
| Hydrops foetalis | |
| Pleural effusion | |
| Pregnancy | |